Pemvidutide
Overview
Pemvidutide is a dual receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors, designed to combine the insulinotropic and appetite-suppressing effects of GLP-1 with the energy expenditure and lipolytic actions of glucagon. This balanced co-agonist strategy aims to achieve superior weight loss and metabolic benefits compared to GLP-1 monotherapy while mitigating the hyperglycemic effects of isolated glucagon receptor activation.
Mechanism of Action
The peptide architecture incorporates amino acid modifications to optimize receptor binding affinity and pharmacokinetic duration.
Research Summary & Key Findings
Phase 2 trial data presented at major endocrinology conferences in 2023 and 2024 reported substantial weight reductions exceeding 10 percent at 16 weeks in patients with obesity, along with improvements in lipid profiles and liver fat content. The compound is advancing through mid-stage development with ongoing trials in both obesity and metabolic dysfunction-associated steatohepatitis, though peer-reviewed publications are still emerging.
Clinical Status
Pemvidutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed — "Pemvidutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Pemvidutide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Pemvidutide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsStart Your Consultation
Get an AI-proposed Pemvidutide protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Pemvidutide.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.